对药物的抗胆固醇负担尺度的药理动力学和药理动力学考虑
Shizuo Yamada1, Masae Mochizuki1, Kazutaka Atobe2
1Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
Geriatrics & gerontology international
|October 24, 2023
概括
在老年人中,多种药物存在由于抗胆固醇副作用的风险. 考虑到药理动力学和药理动力学因素的新尺度,可以更准确地评估老年人抗胆固醇负担.
科学领域:
- 老年人药理学老年人药理学
- 在老年人中药物安全.
- 药理动力学和药理动力学
背景情况:
- 老年人经常通过各种药物 (多药) 管理多种系统性疾病.
- 抗胆固醇副作用在这个人群中是一个重大问题.
- 目前的抗胆固醇负担评级可能缺乏准确性.
研究的目的:
- 提出一种更准确的方法来评估老年人的抗胆固醇负担.
- 通过结合先进的药理学因素,提高抗胆固醇负担评级的精度.
- 为了减少多种药物治疗的老年患者的抗胆固醇不良事件.
主要方法:
- 考虑药物动力学因素,包括生物相药物度和活性代谢物.
- 结合药理动力学因素,如肌肉蛋白受体介导的作用.
- 开发一种基于药理证据的药物负担量表.
主要成果:
- 拟议的尺度旨在提高抗胆固醇负担评估的准确性.
- 预计PK/PD因素的整合将提供更精确的风险评估.
- 预计这种方法将有助于减少抗胆性不良事件.
结论:
- 基于药理证据的药理尺度为评估抗胆固醇负担提供了更优的工具.
- 准确的评估对于管理老年人多药性治疗至关重要.
- 这种精细的方法可以带来更好的患者安全和降低风险.
相关概念视频
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.2K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.2K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
1.0K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.0K
Cholinergic Antagonists: Pharmacokinetics
497
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
497
Cholinergic Antagonists: Pharmacological Actions
1.1K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.1K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
698
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
698
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
167
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
167


